(Melanoma) Is Imfinzi + Ceralasertib Effective?
Medical Supporter — إشعار معلوماتي
هذه المقالة ملخص لمعلومات طبية دولية وليست نصيحة طبية، ولا يمكن أن تحل محل تشخيص طبيبك المعالج أو خطة العلاج. المعلومات المعروضة مجمّعة من منشورات عامة وبيانات رسمية لكبرى المؤسسات الطبية اليابانية؛ وتختلف ملاءمة ونتائج أي علاج من مريض لآخر ويجب أن يقيّمها طبيب مؤهل لكل حالة على حدة.
On October 25, 2021, R. Kim and colleagues from Samsung Medical Center published results in Annals of Oncology from a Phase II clinical trial evaluating the anti-PD-L1 antibody Imfinzi (durvalumab) plus the oral ATR inhibitor ceralasertib in metastatic malignant melanoma patients who had progressed on prior anti-PD-1 antibody therapy.
This Phase II trial enrolled 30 patients with metastatic malignant melanoma who had progressed on prior anti-PD-1 antibody therapy. Patients received Imfinzi (1500 mg) plus ceralasertib (240 mg twice daily on Days 15–28) in 4-week treatment cycles. The primary endpoint was objective response rate (ORR). Prior anti-PD-1 therapies received included Keytruda, Opdivo, and chemotherapy, with a maximum of 3 prior lines of treatment.
Results:
- Primary endpoint ORR: 31.0%
- Disease control rate: 63.3%
- Median duration of treatment: 8.8 months
- Median progression-free survival: 7.1 months
- Median overall survival: 14.2 months
Safety:
All-grade adverse events: anemia 76.7%, anorexia 66.7%, thrombocytopenia 63.3%, nausea 56.7%. Grade ≥3 hematologic adverse events occurred in 53.3%: anemia 33.3%, thrombocytopenia 23.4%, neutropenia 16.7%.
Based on the Phase II trial results, R. Kim and colleagues concluded that durvalumab (Imfinzi) plus ceralasertib demonstrated favorable antitumor activity in metastatic malignant melanoma patients who had progressed on prior anti-PD-1 antibody therapy.
Source: https://www.annalsofoncology.org/article/S0923-7534(21)04545-2/fulltext
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
هل تفكر في تلقّي العلاج في اليابان؟ هل تحتاج إلى معلومات ومساعدة؟
نساعدك في تنظيم المعلومات اللازمة للسفر الطبي إلى اليابان، والتواصل مع المؤسسات الطبية اليابانية، وترتيب استشارة رأي ثانٍ.الاستشارة الأولى مجانية؛ سيساعدك المستشار على توضيح الخطوات التالية.
Figure 1